The recommendations surround important updates to standard criteria that are commonly used despite being decades old.

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Crohn’s and Colitis Canada and AbbVie Canada are proud to announce the 2026 recipients of the AbbVie IBD Scholarship Program. Fifteen students from across ...

The Crohn's & Colitis Foundation will host its 59th Annual Gala at the Edison Ballroom, featuring Broadway performances and celebrating 25 years of ...

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for sys ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could ...

AbbVie ABBV announced that the European Commission ("EC") has approved its blockbuster immunology drug, Rinvoq (upadacitinib), for a new indication. The drug is approved in the European Union for the ...

This article selects and organizes clinical trials from ClinicalTrials.gov (CTgov) that were 'newly registered' or had a ...

Each year, hundreds of students apply for the AbbVie Immunology Scholarship, with hopes of receiving the award. The scholarship is designed to support students who are living with chronic inflammatory ...

The math is visible. TREMFYA's $5.16 billion in 2025 replaces only about half of Stelara's 2023 peak. J&J's $10 billion peak projection for TREMFYA would close that gap, but only if the drug sustains ...